Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 18/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879396 | 0.80 | S1PR3 (0.55) | S1PR3 | |
| SCHEMBL4879000 | 0.74 | S1PR3 (0.53) | S1PR3AR | |
| SCHEMBL4883584 | 0.72 | S1PR3 (0.68) | S1PR3PLA2G2AAR | |
| SCHEMBL2005332 | 0.69 | PLA2G2A (0.52) | S1PR3PLA2G2A | |
| SCHEMBL4881699 | 0.69 | S1PR3 (0.79) | S1PR3 | |
| SCHEMBL337115 | 0.68 | S1PR3 (0.61) | S1PR3 | |
| SCHEMBL4885348 | 0.68 | S1PR3 (0.40) | S1PR3 | |
| SCHEMBL16373458 | 0.66 | S1PR3 (0.55) | S1PR3 | |
| SCHEMBL291421 | 0.66 | S1PR3 (0.65) | S1PR3PLA2G2A | |
| SCHEMBL2010316 | 0.66 | S1PR3 (0.65) | S1PR3PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524917-B2 | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | ALLERGAN, INC. | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | PTGIR, S1PR1, TBXA2R | S1PR3 6/4885PLA2G2A 114/4885AR 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.